| Patents for A61P 7 - Drugs for disorders of the blood or the extracellular fluid (67,065) |
|---|
| 04/14/2004 | EP1407779A1 Use of ghrelin for treating low body weight and body fat in gastrectomized individuals |
| 04/14/2004 | EP1407768A2 The potassium channel opener retigabine for the treatment of diseases |
| 04/14/2004 | EP1406930A2 Isolated molecules comprising epitopes containing sulfated moieties, antibodies to such epitopes, and uses thereof |
| 04/14/2004 | EP1406929A2 Glycoprotein vi fusion proteins |
| 04/14/2004 | EP1406922A2 Protection, restoration, and enhancement of erythropoietin-responsive cells, tissues and organs |
| 04/14/2004 | EP1406908A1 Morpholine-bridged pyrazolopyridine derivatives |
| 04/14/2004 | EP1406878A1 4-(benzylidene-amino)-3-(methylsulfanyl)-4h-(1, 2, 4) triazin-5-one derivatives having a pde-iv inhibiting and tnf-antagonistic effect for the treatment of cardiac diseases and allergies |
| 04/14/2004 | EP1406875A1 N-heterocyclic inhibitors of tnf-alpha expression |
| 04/14/2004 | EP1406866A1 Inhibitors of the ice/ced-3 family of cysteine proteases |
| 04/14/2004 | EP1406858A1 Substituted 4-aminocyclohexanols |
| 04/14/2004 | EP1406697A2 Use of magnesium for preventing in-stent thrombosis and complications after arterial angioplasty with stent placement |
| 04/14/2004 | EP1406696A1 Use of compositions comprising cyclooxygenase-2 selective inhibitors in combination with radiation for inhibition or prevention of cardiovascular disease |
| 04/14/2004 | EP1406664A2 Targeting chemical compounds to cells |
| 04/14/2004 | EP1406660A1 Combination of an aldosterone receptor antagonist and an hmg coa reductase inhibitor |
| 04/14/2004 | EP1406656A2 METHODS OF ADMINISTERING ANTI-TNF$g(a) ANTIBODIES |
| 04/14/2004 | EP1406650A1 Use of poly-glu, tyr and t cells treated therewith for neuroprotection therapy |
| 04/14/2004 | EP1406644A2 Modified proteins, designer toxins, and methods of making thereof |
| 04/14/2004 | EP1406626A2 Sulphonyl aryl hydroxamates and their use as mmp inhibitors |
| 04/14/2004 | EP1406622A2 Dipeptidyl peptidase inhibitors for the treatment of diabetes |
| 04/14/2004 | EP1406613A1 Organic nitrate-based compounds for the treatment of vasculopathies |
| 04/14/2004 | EP1406612A1 Use of heterocyclic and benzoheterocyclic polyamides structurally related to the natural antibiotic dystamycin a for the treatment of beta-thalassaemia |
| 04/14/2004 | EP1406611A2 Method for treating fibrotic diseases or other indications |
| 04/14/2004 | EP1406609A2 Substituted aryl compounds as novel cyclooxygenase-2 selective inhibitors, compositions and methods of use |
| 04/14/2004 | EP1406608A2 Nitrosated and nitrosylated nebivolol and its metabolites, compositions and methods of use |
| 04/14/2004 | EP1406602A2 Use of sulfonyl aryl or heteroaryl hydroxamic acids and derivatives thereof as aggrecanase inhibitors |
| 04/14/2004 | EP1230252B1 Beta-d-5-thioxylose derivatives, preparation method and therapeutic use |
| 04/14/2004 | EP1189583A4 Indole derivatives |
| 04/14/2004 | EP1137432B1 Use of protein c for the treatment of thrombocytopenic purpura and hemolytic uremic syndrome |
| 04/14/2004 | EP1115708B1 Aminoalkyl-3,4-dihydroquinoline derivates as no-synthase inhibitors |
| 04/14/2004 | EP1039917B1 Pharmaceutical composition comprising ticlopidine and ginkgo biloba extract |
| 04/14/2004 | EP1015490B1 No-modified hemoglobins and uses therefor |
| 04/14/2004 | EP0979240B1 Serine protease inhibitors |
| 04/14/2004 | EP0935465B1 Novel substituted imidazole compounds |
| 04/14/2004 | CN1489596A šŒ-substituted š�-aminoethyl phosphonates |
| 04/14/2004 | CN1489590A Compounds specific to adenosine A1, A2, and A3 receptor and uses thereof |
| 04/14/2004 | CN1489588A Thiazolyl-oxazolyl-pyrrolyl-and imidazolyl-acid amide derivatives useful as inbibitors of PDE 4 isozymes |
| 04/14/2004 | CN1489583A Novel physiologically active substance |
| 04/14/2004 | CN1489578A 3-(3-amidinophenyl)-5-[({[1-(iminoethyl)4-piperidyl} amino)methyl] benzoic acid dihydrochloride and process for preparing same |
| 04/14/2004 | CN1489573A Perfluoronated cycle-containing tertiary amines used as basis for gas-conveying emulsions and preparation method |
| 04/14/2004 | CN1488399A Medicinal use of agkistrodon acutus thrombase for treating hemorrhagic disease |
| 04/14/2004 | CN1488398A Instant freeze-dried fibriogen preparation with anti dry heat treatment |
| 04/14/2004 | CN1488353A Composition for treating ischemic disease |
| 04/14/2004 | CN1145694C Novel human thrombopoietin mutein |
| 04/14/2004 | CN1145693C Amino-terminally truncated MCP-2 as chemokine antagnosits |
| 04/14/2004 | CN1145643C Oligosaccharide mixtures having antithrombotic activity |
| 04/14/2004 | CN1145637C Thio-substituted peptides as inhibitors for metalloproteinases and tnfliberation |
| 04/13/2004 | US6720427 Used to treat abnormal cell growth and central nervous system disorders |
| 04/13/2004 | US6720350 Reducing diminution in vessel lumen area with a therapeutic shunt having a cytoskeletal inhibitor to reduce stenosis or restenosis; taxols, cytochalasins |
| 04/13/2004 | US6720346 Thiazole benzamide derivatives and pharmaceutical compositions for inhibiting cell proliferation |
| 04/13/2004 | US6720321 1,4-disubstituted benzo-fused cycloalkyl urea compounds |
| 04/13/2004 | CA2322963C Methods to increase white blood cell survival after chemotherapy |
| 04/08/2004 | WO2004029242A1 Antibody against enzyme specifically cleaving von villebrand factor and assay system using the same |
| 04/08/2004 | WO2004029192A2 Producing method of tien hsien liquid |
| 04/08/2004 | WO2004029049A1 Novel salt of 2-acylaminothiazole derivative |
| 04/08/2004 | WO2004028564A2 Treatment of pathologies which escape the immune response, using optimised antibodies |
| 04/08/2004 | WO2004028542A1 Use of 4-pyridylmethyl-phthalazine derivatives for the manufacture of a medicament for the treatment of myelodysplastic syndromes |
| 04/08/2004 | WO2004015096A3 Leech extracts for stents |
| 04/08/2004 | WO2004013115A3 Carboxamides, production and use thereof as medicaments____ |
| 04/08/2004 | WO2004009565A3 Acylaminothiazole derivatives, preparation and therapeutic use thereof |
| 04/08/2004 | WO2004003016A3 Marked peptides having affinity for a phospholipid and uses |
| 04/08/2004 | WO2004003015A3 Peptides having affinity for a phospholipid and uses |
| 04/08/2004 | WO2003100087A3 Regulation of novel human asparagine-hydroxylases |
| 04/08/2004 | WO2003097622A3 Synthesis of 2-alkylcysteines, 2-(hydroxylated phenyl)-4-alkylthiazoline-4-carboxylic acids and derivatives thereof |
| 04/08/2004 | WO2003092605A9 Protease inhibitors |
| 04/08/2004 | WO2003086314A3 Tyrosine kinase inhibitors |
| 04/08/2004 | WO2003083135A3 Diagnostics and therapeutics for diseases associated with neuropeptide ff receptor 2 (npff2) |
| 04/08/2004 | WO2003078647A3 Aza-benzothiopyranoindazoles with antitumor activity |
| 04/08/2004 | WO2003070690A3 Novel amino acid derivatives, method for production thereof and pharmaceutical compositions comprising said derivative |
| 04/08/2004 | WO2003066077A3 Diagnostics and therapeutics for diseases associated with neuromedin u1 receptor (nmu1) |
| 04/08/2004 | WO2003018606A9 Casein derived peptides and uses thereof in therapy |
| 04/08/2004 | WO2003012030A3 Isoform-selective inhibitors and activators of pde3 cyclic |
| 04/08/2004 | WO2003011313A8 Osteogenic growth oligopeptides as stimulants of hematopoiesis |
| 04/08/2004 | WO2002092008A3 Use of il-18 inhibitors for the treatement or prevention of sepsis |
| 04/08/2004 | WO2002030470A8 Methods and compositions for nucleic acid delivery |
| 04/08/2004 | US20040068113 Substituted polycyclic aryl and heteroaryl pyridines useful for selective inhibition of the coagulation cascade |
| 04/08/2004 | US20040068109 Activated blood coagulation factor X inhibitor and also to such a pharmaceutical agent and particularly has an excellent activity by oral administration |
| 04/08/2004 | US20040068108 Disaccharide sequences formed by uronic acid and hexose as to form polysaccharides of 8-24 monosaccharide units whose hydroxyl groups are substituted by alkyl or sulphate groups; possible to modulate activities of glycosaminoglycans type |
| 04/08/2004 | US20040068020 Patient oxygenation using stabilized fluorocarbon emulsions |
| 04/08/2004 | US20040067979 N-bridged selective androgen receptor modulators and methods of use thereof |
| 04/08/2004 | US20040067966 Adenosine receptor antagonists and methods of making and using the same |
| 04/08/2004 | US20040067954 Benzoylpyridazines |
| 04/08/2004 | US20040067949 Substituted indoles which are parp inhibitors |
| 04/08/2004 | US20040067946 Phthalatyinone-piperidino-derivatives as pde4 inhibitors |
| 04/08/2004 | US20040067938 Quaternary amines and related inhibitors of factor xa |
| 04/08/2004 | US20040067933 Prevent bile acid transportation; antilipemic agents; anticholesterol agents |
| 04/08/2004 | US20040067918 Combination of an aldosterone receptor antagonist and nicotinic acid or a nicotinic acid derivative |
| 04/08/2004 | US20040067552 Adipocyte complement related protein zacrp14 |
| 04/08/2004 | US20040067518 Isolated nucleic acid comprising a polynucleotide of given sequence; polypeptides; recombinant host cells; useful in diagnosing and treating disorders |
| 04/08/2004 | US20040067504 Novel zacrp8 polypeptides, polynucleotides encoding the polypeptides, and related compositions and methods of using them; useful in the study of collagen dimerization or oligomerization or in formation of fusion proteins |
| 04/08/2004 | US20040067491 Diagnosis of diseases associated with metabolism |
| 04/08/2004 | US20040067232 Methods for treating autoimmune diseases in a subject and in vitro diagnostic assays |
| 04/08/2004 | US20040067230 Administering factor XIII. |
| 04/08/2004 | US20040067218 Extramedullary adipose tissue cells and use thereof for regenerating hematopoietic and muscular tissue |
| 04/08/2004 | CA2840692A1 Fvii or fviia variants having increased clotting activity |
| 04/08/2004 | CA2499738A1 Use of 4-pyridylmethyl-phthalazine derivatives for the manufacture of a medicament for the treatment of myelodysplastic syndromes |
| 04/08/2004 | CA2498383A1 Treatment of pathologies which escape the immune response, using optimised antibodies |
| 04/07/2004 | EP1405863A1 Concentrate of a factor VIII:C-containing von-Willebrand-factor and a process for producing it |
| 04/07/2004 | EP1405852A1 Diamine derivatives |
| 04/07/2004 | EP1405083A2 Natural ligand of gpcr chemr23 and uses thereof |
| 04/07/2004 | EP1404876A2 Interferon alpha-14 polymorphism |